Skip to main
PEN
PEN logo

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 35%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc demonstrated significant growth in December, achieving its highest monthly volume of VTE procedures ever, with overall thrombectomy sales increasing by 16.9% and total sales for embolization and aspiration (E&A) rising by 5.1%. The company reported a year-over-year improvement in non-GAAP operating margin, which increased by 200 basis points, driven by enhanced gross margins and reduced research and development expenses, culminating in an operating margin of 15.1%. Additionally, the gross margin rose by 170 basis points to 67.4%, indicating strong product mix benefits and improved operational productivity.

Bears say

Penumbra Inc faces a challenging outlook, with projected revenue growth anticipated to decline to less than 12% due to lower-than-expected contributions from new products and a lag in profitability improvements. Recent revenue estimates for 2025 and 2026 have been lowered to $1.349 billion and $1.531 billion, respectively, reflecting concerns over market share loss to competitors and persistent risks related to product launches and supply chain disruptions. Additionally, pressures in the international market, particularly in China, further exacerbate the company's financial challenges.

Penumbra (PEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 35% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 20 analysts, Penumbra (PEN) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $288.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $288.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.